Skip to main content
Pulike Biological Engineering,Inc. logo

Pulike Biological Engineering,Inc. — Investor Relations & Filings

Ticker · 603566 ISIN · CNE1000025N0 Shanghai Stock Exchange Manufacturing
Open in API
Filings indexed 1,080 across all filing types
Latest filing 2024-01-03 Board/Management Inform…
Country CN China
Listing Shanghai Stock Exchange 603566

About Pulike Biological Engineering,Inc.

http://en.pulike.com.cn/

Pulike Biological Engineering, Inc. specializes in the research, development, and production of veterinary biological products and pharmaceutical preparations. The company focuses on animal disease prevention through the manufacture of high-end vaccines, diagnostic reagents, and veterinary medicines. Its product range primarily serves the swine and poultry sectors, featuring advanced biologicals such as genetically engineered vaccines and synthetic peptide products. Pulike maintains a strong emphasis on technological innovation, utilizing national-level research platforms to develop solutions for complex animal health challenges. The company’s core activities encompass the entire value chain from basic biotechnology research to the commercialization of veterinary health solutions, aiming to improve livestock productivity and biosecurity.

Recent filings

Filing Released Lang Actions
普莱柯第五届监事会第六次会议决议公告
Board/Management Information Classification · 95% confidence The document is a resolution announcement from the Supervisory Board of a company regarding the approval of expected related party transactions for the upcoming fiscal year. It includes details about the meeting date, attendance, and voting results. There is no financial data, no detailed report, and no mention of an annual or interim report. The document is a formal announcement of a board/committee decision rather than a financial report or regulatory filing. Therefore, it fits best under Board/Management Information (MANG), which covers announcements of company board or management decisions and changes.
2024-01-03 Chinese
普莱柯第五届董事会第八次会议决议公告
Board/Management Information Classification · 95% confidence The document is a formal announcement of resolutions passed at a board meeting of 普莱柯生物工程股份有限公司. It details the meeting date, attendance, and voting results on various board matters including amendments to company bylaws and committee member changes. There is no financial data or report content, but rather governance and management decisions. This fits the category of Board/Management Information (MANG), which covers announcements of changes in the company's board or senior management and related board resolutions. The document length is short and it is not a report or presentation, so it is not an Annual Report or Investor Presentation. Therefore, the classification is MANG with high confidence.
2024-01-03 Chinese
普莱柯生物工程股份有限公司章程
Governance Information Classification · 100% confidence The document is titled '公司章程' which translates to 'Company Articles of Association' or 'Company Bylaws'. It contains detailed chapters on company organization, shareholder rights, board of directors, management, financial accounting, audit, and other governance-related matters. It is a comprehensive internal governance document outlining the company's rules and structure rather than a report on financial performance or an announcement. There are no indications of financial statements, earnings data, or meeting results. The document is not a report publication announcement or a certification. It fits the description of Governance Information (CGR), which covers the company's internal rules, board structure, and governance practices.
2024-01-03 Chinese
普莱柯关于修订公司章程的公告
Governance Information Classification · 95% confidence The document is an announcement from 普莱柯生物工程股份有限公司 regarding the revision of the company's articles of association (公司章程). It details specific amendments to the articles, especially related to the board committees and profit distribution policies. The document is a formal announcement of these changes and states that the amendments will be submitted to the shareholders' meeting for approval and subsequent filing with the relevant authorities. There is no financial data, audit information, or report content; rather, it is a regulatory announcement about governance documents and corporate bylaws. This fits best under Governance Information (CGR), which covers reports detailing the company's internal rules, board structure, and governance practices.
2024-01-03 Chinese
普莱柯生物工程股份有限公司信息披露事务管理制度
Governance Information Classification · 95% confidence The document is titled '信息披露事务管理制度' which translates to 'Information Disclosure Management System'. It details the company's policies, principles, responsibilities, and procedures for information disclosure, including references to regulatory laws, securities regulations, and stock exchange rules. It covers definitions of information disclosure obligations, types of reports (annual, interim, quarterly, and temporary reports), disclosure timing, content requirements, and roles of directors, supervisors, and senior management in disclosure. It also discusses confidentiality, handling of insider information, and penalties for non-compliance. The document is a comprehensive internal governance and compliance manual for information disclosure rather than an actual financial report or announcement. It does not contain financial statements, earnings data, or specific event announcements. Therefore, it fits best under Governance Information (CGR), as it details the company's internal rules and governance practices related to information disclosure.
2024-01-03 Chinese
普莱柯关于预计2024年度日常关联交易的公告
Regulatory Filings Classification · 95% confidence The document is an announcement from 普莱柯生物工程股份有限公司 regarding the expected daily related party transactions for the year 2024. It includes detailed information about the nature, amounts, and parties involved in these related party transactions, as well as the company's internal approval process and compliance with relevant regulations. The document does not contain financial statements or comprehensive financial performance data, nor is it a transcript, presentation, or voting result. It is a regulatory announcement about related party transactions, which is a common type of disclosure required by stock exchanges to inform shareholders and the market about potential conflicts of interest and transaction details. Given the content and purpose, this fits best under the category of Regulatory Filings (RNS), which covers general regulatory announcements and compliance documents that do not fit other specific categories.
2024-01-03 Chinese

Browse filings by year

12 years

Report missing filing

Can't find a specific document? Let us know and we'll add it within 24 hours.

We will notify you once the filing is added.
Report sent
Thank you. We will check the data and update it shortly.